Book launch "Data science, artificial intelligence and machine learning in drug development"

At the seminar "Application of artificial intelligence in drug development" recently held in Hanoi, the book "Data science, artificial intelligence and machine learning in drug development" edited by Dr. Harry Yang was introduced to Vietnamese readers through the translation of Hoai Son, edited by Associate Professor, Dr. Le Van Truyen.

The book “Data Science , Artificial Intelligence and Machine Learning in Drug Development” is a must-read for students and professionals in the pharmaceutical industry.

Currently, many research institutes and large pharmaceutical corporations in the world have been applying data science, artificial intelligence (AI) and machine learning (ML) in their operations and research, aiming to create major changes in the drug development process. In that context, the book "Data science, artificial intelligence and machine learning in drug development" has met the urgent needs of those working in the pharmaceutical industry and students of pharmacy schools in Vietnam.

The book is edited by Dr. Harry Yang, who has many years of experience in the field of biological and pharmaceutical data, from drug target discovery to clinical research and post-approval.

Overview of the seminar on AI application in drug development and book launch in Hanoi.

The book "Data Science, Artificial Intelligence and Machine Learning in Drug Development" published by Medinsights - a medical knowledge and book publishing brand of Alpha Books, is 484 pages long and includes 13 chapters. Each chapter discusses a specific aspect of drug research and development with data science, artificial intelligence (AI) and machine learning (ML), in which data science is considered an important "foundation" in drug development.

In fact, AI is only effective when there is enough quality data, in which data science and AI are applied in many stages of drug development including: drug discovery, preclinical, clinical trials; production and commercialization. Information from the book has provided readers with an overall outline of the digital transformation of the pharmaceutical industry under the impact of data science, AI and machine learning.

Many chapters in the book delve into AI in drug discovery, AI-assisted clinical trials, machine learning applications for precision medicine, and content on drug safety and pharmacovigilance based on big data. The specific applications of data science, artificial intelligence and machine learning in the book are illustrated by the authors with the story of Exscientia Company (UK) in developing cancer drugs using AI and to date has had products put into clinical trials.

Another example introduced in the book is Insilico Medicine (USA) using AI to develop pulmonary fibrosis drugs, shortening the time from 4-5 years to less than 18 months, along with a series of projects by leading pharmaceutical companies in the world: Bayer, Novartis, Pfizer cooperating with AI companies to accelerate the development of new drugs.

It can be seen that data science, artificial intelligence and machine learning do not replace scientists, but they act as “super-speed assistants” in processing huge amounts of data, suggesting research directions, and reducing the very high failure rate in traditional drug development.

In Vietnam, the application of artificial intelligence in drug development is still quite new, mainly in startups or small research centers, and has only stopped at the level of applying AI to support patient data analysis and trial design, without any clear commercial products. However, this will be significantly improved when the medical data infrastructure, technology and human resource capacity are improved - and the book Data Science, Artificial Intelligence and Machine Learning in Drug Development can contribute to this process.

According to Associate Professor, Dr. Le Van Truyen, former Deputy Minister of Health, Senior Pharmaceutical Expert at the book launch seminar.

According to Associate Professor, Dr. Le Van Truyen, former Deputy Minister of Health, Senior Pharmaceutical Expert, with the nature of both a comprehensive overview document and a practical guideline, the book "Data Science, Artificial Intelligence and Machine Learning in Drug Development" will help readers - from technology experts to medical researchers - grasp how to exploit the power of information technology to accelerate the process of discovering, testing and soon bringing to market new safe and effective drugs, serving the mission of protecting human health.

"With easy-to-understand language, intuitive illustrations and practical examples, the book is also suitable for doctors, pharmacists, policy makers, health managers, medical and pharmaceutical students and all those interested in the development of modern medicine in the patient-centered era, towards a precise and humane medicine with the help of advanced science and technology," Associate Professor, Dr. Le Van Truyen commented.

With easy-to-understand language, intuitive illustrations and practical examples, the book is also suitable for doctors, pharmacists, policy makers, health managers, medical and pharmaceutical students and all those interested in the development of modern medicine in the patient-centered era, towards a precise and humane medicine with the help of advanced science and technology.

ASSOCIATE PROFESSOR, DOCTOR LE VAN TRUYEN

Evaluating the book's content, Associate Professor, Dr. Pham Thi Thuy Van - Head of the Department of Pharmacology and Clinical Pharmacy, Hanoi University of Pharmacy, said: The book "Data science, artificial intelligence and machine learning in drug development" is an in-depth, updated, highly oriented document on the application of data science, artificial intelligence (AI) and machine learning (ML) in drug research and development, both in the pre- and post-licensing stages.

“From the perspective of a clinical dossier review expert and a member of the Drug Licensing Advisory Council (Ministry of Health), I especially appreciate the chapters discussing AI-assisted clinical trials, precision medicine, real-world evidence (RWE) and big data-based pharmacovigilance - factors that are increasingly of interest to national drug regulatory agencies in assessing the benefits-risks and cost-effectiveness of drugs,” Ms. Pham Thi Thuy Van shared.

Mr. Nguyen Canh Binh, Chairman of the Board of Directors of Alpha Books, spoke at the book launch ceremony.

The book also addresses changes in regulatory regulations to adapt to technological developments, including the construction of a legal system capable of guiding, analyzing and interpreting big data using modern technologies, including AI and ML… With clear language, practical examples and an interdisciplinary approach, the book contributes to promoting digital transformation in the pharmaceutical industry, towards a precise, effective and humane medicine and pharmacy.

In addition, the book is also a comprehensive, updated handbook describing the process of researching and developing new drugs connected to big data sources through AI to shorten time and save resources. This is extremely useful for pharmacists, doctors and those working in the field of drug research and development.

NGUYEN CUONG

Source: https://nhandan.vn/ra-mat-sach-khoa-hoc-du-lieu-tri-tue-nhan-tao-va-hoc-may-trong-phat-trien-thuoc-post911851.html